Press Release: Availability of the Q2 2024 Aide-mémoire

25.06.24 19:32 Uhr

Werte in diesem Artikel
Aktien

96,31 EUR 3,39 EUR 3,65%

Availability of the Q2 2024 Aide-mémoire

Paris, France – June 25, 2024. Sanofi announced that its Q2 2024 Aide-mémoire is available on the "Investors" page of the company's website:

https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/q2-results-2024

As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items and exclusivity losses as well as the foreign currency impact and share count. Sanofi's second-quarter 2024 results will be published on July 25, 2024.

About Sanofi
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations 
Sandrine Guendoul?|?+ 33 6 25 09 14 25 |?sandrine.guendoul@sanofi.com 
Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com  
Victor Rouault?|?+ 33 6 70 93 71 40 |?victor.rouault@sanofi.com 
Timothy Gilbert?|?+ 1 516 521 2929 | timothy.gilbert@sanofi.com 

Investor Relations 
Thomas Kudsk Larsen |+ 44 7545 513 693 | thomas.larsen@sanofi.com  
Alizé Kaisserian?|?+ 33 6 47 04 12 11 | alize.kaisserian@sanofi.com 
Arnaud Delépine?|?+ 33 6 73 69 36 93 | arnaud.delepine@sanofi.com 
Felix Lauscher?|?+ 1?908?612 7239 | felix.lauscher@sanofi.com  
Keita Browne?|?+ 1 781 249 1766 | keita.browne@sanofi.com 
Nathalie Pham?|?+ 33 7 85 93 30 17 | nathalie.pham@sanofi.com 
Tarik Elgoutni | + 1 617 710 3587 | tarik.elgoutni@sanofi.com  
Thibaud Châtelet | + 33 6 80 80 89 90 |?thibaud.chatelet@sanofi.com 

Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects”, "anticipates”, "believes”, "intends”, "estimates”, "plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation,? trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors” and "Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2023. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.


 

Attachment


Ausgewählte Hebelprodukte auf Sanofi

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Sanofi

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Sanofi S.A.

Analysen zu Sanofi S.A.

DatumRatingAnalyst
16.07.2024Sanofi NeutralJP Morgan Chase & Co.
10.07.2024Sanofi SellDeutsche Bank AG
09.07.2024Sanofi BuyUBS AG
08.07.2024Sanofi BuyJefferies & Company Inc.
03.07.2024Sanofi BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
DatumRatingAnalyst
09.07.2024Sanofi BuyUBS AG
08.07.2024Sanofi BuyJefferies & Company Inc.
03.07.2024Sanofi BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
02.07.2024Sanofi BuyJefferies & Company Inc.
02.07.2024Sanofi BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
DatumRatingAnalyst
16.07.2024Sanofi NeutralJP Morgan Chase & Co.
03.07.2024Sanofi NeutralJP Morgan Chase & Co.
24.06.2024Sanofi NeutralJP Morgan Chase & Co.
03.06.2024Sanofi NeutralJP Morgan Chase & Co.
10.05.2024Sanofi NeutralJP Morgan Chase & Co.
DatumRatingAnalyst
10.07.2024Sanofi SellDeutsche Bank AG
13.05.2024Sanofi SellDeutsche Bank AG
29.04.2024Sanofi SellDeutsche Bank AG
20.02.2024Sanofi SellDeutsche Bank AG
06.02.2024Sanofi SellDeutsche Bank AG

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Sanofi S.A. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"